Fuse Diagnostics
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Fuse Diagnostics firmographics
Firmographics- Name
- Fuse Diagnostics
- Legal name
- Fuse Diagnostics Limited
- Website
- https://fuse-dx.com/
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Fuse Diagnostics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
- akta.pro secondary industries
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Rapid On-Site Environmental Testing Kits & Instruments (Lateral Flow, PCR, ATP Devices) (AFALAEAK), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Fuse Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Fuse Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others
Revenue model
- Diagnostic Test Devices and Disposables: Fuse generates revenue from the sale of its diagnostic test devices and single-use disposable test kits. The Flip and Apex platforms are designed as low-cost, disposable, single-use products. Revenue is derived from product sales to end users in industrial, food, water, clinical, and veterinary sectors through direct sales and distribution partners.
- Distribution Partnership Revenue: Revenue flows through distribution partnerships with Stratech Scientific (UK & Ireland) and CliniSciences (major European countries), where distributors purchase and resell Fuse products to end customers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Flip and Apex diagnostic test products are sold as single-use, low-cost disposable devices. Specific pricing tiers are not publicly disclosed. |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels3 records
Fuse Diagnostics product offering
Product offeringCore offering
Fuse Diagnostics develops and sells proprietary, instrument-free, disposable molecular diagnostic test devices built on its multianalytic amplification chemistry. The Flip product range delivers rapid, laboratory-quality pathogen testing for industrial, food, water, and veterinary settings, while the Apex product range is designed for point-of-care clinical diagnostics such as sexually transmitted and respiratory infections. The first commercial product, Flip Mycoplasma, detects mycoplasma contamination in cell cultures with PCR-quality results in 12 minutes using a visual read-out and no specialist equipment.
Product overview
Fuse Diagnostics offers two distinct diagnostic platforms: Flip and Apex. Flip is a versatile platform for rapid point-of-need testing in industrial, food, water, and veterinary sectors, delivering laboratory-quality results in a low-cost, disposable device without specialist equipment. Apex is designed for point-of-care clinical diagnostics, targeting applications such as respiratory and sexually transmitted infections. The Flip product range includes Flip Mycoplasma (launched), and upcoming tests for Legionella and Avian Influenza. Apex CT/NG targets Chlamydia and Gonorrhoea diagnostics. Both platforms leverage proprietary multianalytic amplification chemistries for rapid results.
Differentiator
Problem solved
Functional benefit
Brands
- Flip: A versatile platform for rapid onsite testing across Industry, Food and Veterinary sectors. Flip delivers definitive laboratory quality results in an easy-to-use, low-cost device without any specialist equipment. The first product, Flip Mycoplasma, detects cell culture contamination with laboratory PCR quality results in just 12 minutes.
- Apex
Products and services
- Flip Mycoplasma First product in the Flip product range; a disposable, instrument-free molecular test that detects mycoplasma contamination in cell cultures in 12 minutes with laboratory PCR-quality accuracy and a clear visual read-out, designed for industrial bioprocessing QC, food, water, and veterinary users.
- Flip Nest USB-C powered accessory designed for use with Flip tests, enabling rapid molecular-quality testing in any location without mains power or specialist instrumentation.
Quantifiable outcome
- Flip Mycoplasma delivers laboratory PCR-quality results in 12 minutes
- +2 more outcomes
Companies that use Fuse Diagnostics
Customer profileSegments3 records
Ideal customer profiles3 records
Fuse Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Fuse Diagnostics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- CliniSciencescoreFuse Diagnostics signed a distribution agreement with CliniSciences for the launch of Flip Mycoplasma in Europe. The agreement covers major European countries including France, Germany, Spain, and Italy. CliniSciences is a leading European distributor for life science and diagnostic labs, acting as a key player linking manufacturers with researchers in Europe and North America.
- Stratech ScientificcoreFuse Diagnostics and Stratech Scientific formed a strategic distribution partnership for the commercialisation of Flip Mycoplasma in the UK and Ireland. Stratech is a leading life science company with 40 years of experience, providing reagents and solutions to academic research, pharmaceutical companies, and clinical diagnostics. Flip Mycoplasma is also available for purchase through Stratech's catalogue.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Fuse Diagnostics competitors and assessment
Company assessmentDirect peers
- Sherlock Biosciences: US-based molecular diagnostics company using CRISPR-based amplification for rapid, instrument-free nucleic acid detection. Directly comparable because it acquired Sense Biodetection (Fuse founders' prior company) and operates in the same rapid, decentralized molecular diagnostic category.
- QuantuMDx: UK-based developer of the Q-POC rapid molecular point-of-care diagnostic platform. Directly comparable as a similarly-sized UK molecular POCT company targeting decentralised, near-patient testing for infectious disease.
- Binx Health: Developer of the io molecular platform for rapid, instrument-based CT/NG STI testing at the point of care. Directly comparable because it targets the same clinical use case as Fuse's Apex CT/NG assay (rapid molecular STI diagnostics).
- Genomadix: UK-based developer of a portable, rapid molecular testing platform (Cube). Directly comparable as a small UK molecular POCT company delivering laboratory-grade results in a compact, near-patient format.
- T2 Biosystems: US molecular diagnostics company with T2 Magnetic Resonance-based rapid panels for sepsis and other infections. Comparable as a small-cap molecular diagnostics company pursuing rapid, decentralised detection of pathogens without traditional lab workflows.
Broad incumbents
- Cepheid (Danaher): Subsidiary of Danaher and the established leader in molecular POCT with the GeneXpert platform. Broad incumbent offering overlapping molecular diagnostic capabilities across infectious disease, but as part of a much larger portfolio and reliant on a proprietary instrument.
- Abbott Diagnostics: Global diagnostics giant with rapid molecular platforms including ID NOW. Broad incumbent operating across immunoassay, molecular and POC diagnostics with deep regulatory clearances and global hospital penetration.
- Hologic: US diagnostics company with the Panther molecular system widely used for STI screening including CT/NG. Broad incumbent in women's health and molecular diagnostics with large installed base and FDA-cleared assays overlapping Fuse's Apex CT/NG target use case.
- bioMérieux: French in vitro diagnostics company with molecular (BioFire FilmArray), industrial microbiology and food pathogen testing product lines. Broad incumbent spanning clinical and industrial microbiology - the same verticals Fuse addresses with Flip and Apex.
Others
- Sense Biodetection (acquired by Sherlock Biosciences): Fuse founders' previous company, which developed the Veros instrument-free rapid molecular COVID-19 test and was acquired by Sherlock Biosciences in 2023. Relevant as the technological predecessor and proof point for Fuse's founding team, though it no longer operates independently.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Fuse Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fuse Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
Fuse Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fuse Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fuse Diagnostics
What does Fuse Diagnostics do?
Fuse Diagnostics develops and sells proprietary, instrument-free, disposable molecular diagnostic test devices built on its multianalytic amplification chemistry. The Flip product range delivers rapid, laboratory-quality pathogen testing for industrial, food, water, and veterinary settings, while the Apex product range is designed for point-of-care clinical diagnostics such as sexually transmitted and respiratory infections. The first commercial product, Flip Mycoplasma, detects mycoplasma contamination in cell cultures with PCR-quality results in 12 minutes using a visual read-out and no specialist equipment.
Is Fuse Diagnostics a public or private company?
Fuse Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Fuse Diagnostics founded?
Fuse Diagnostics was founded in 2022. It employs 1 to 10 people.
Where is Fuse Diagnostics based?
Fuse Diagnostics is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Fuse Diagnostics make money?
Two revenue lines are on record. Diagnostic Test Devices and Disposables are the primary driver. The others are distribution Partnership Revenue.
Who are Fuse Diagnostics's main competitors?
Direct peers on record are Sherlock Biosciences, QuantuMDx, Binx Health, Genomadix and T2 Biosystems. Broad incumbents are Cepheid (Danaher), Abbott Diagnostics, Hologic and bioMérieux. Sense Biodetection (acquired by Sherlock Biosciences) is listed as an others.
Does Fuse Diagnostics have an API?
No public API is recorded for Fuse Diagnostics.
What industry is Fuse Diagnostics in?
Fuse Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis). Its NAICS code is 325413 and its SIC code is 2835.